Incyte/$INCY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Incyte
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Ticker
$INCY
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
2,617
ISIN
US45337C1027
Website
Incyte Metrics
BasicAdvanced
$13B
704.66
$0.10
0.90
-
Price and volume
Market cap
$13B
Beta
0.9
52-week high
$82.15
52-week low
$53.56
Average daily volume
2M
Financial strength
Current ratio
2.111
Quick ratio
1.747
Long term debt to equity
0.89
Total debt to equity
1.176
Interest coverage (TTM)
83.55%
Profitability
EBITDA (TTM)
303.279
Gross margin (TTM)
37.80%
Net profit margin (TTM)
0.48%
Operating margin (TTM)
4.75%
Effective tax rate (TTM)
93.24%
Revenue per employee (TTM)
$1,690,000
Management effectiveness
Return on assets (TTM)
2.03%
Return on equity (TTM)
0.47%
Valuation
Price to earnings (TTM)
704.664
Price to revenue (TTM)
3.089
Price to book
3.61
Price to tangible book (TTM)
3.89
Price to free cash flow (TTM)
47.208
Free cash flow yield (TTM)
2.12%
Free cash flow per share (TTM)
144.83%
Growth
Revenue change (TTM)
17.13%
Earnings per share change (TTM)
-97.06%
3-year revenue growth (CAGR)
12.32%
10-year revenue growth (CAGR)
22.48%
3-year earnings per share growth (CAGR)
-71.51%
10-year earnings per share growth (CAGR)
-6.91%
What the Analysts think about Incyte
Analyst ratings (Buy, Hold, Sell) for Incyte stock.
Bulls say / Bears say
Incyte raised its 2024 sales forecast for Jakafi to between $2.74 billion and $2.77 billion, reflecting strong demand across multiple indications. (reuters.com)
Opzelura's sales surged by 52% to $139 million in Q3 2024, indicating robust market adoption and potential for future growth. (reuters.com)
Incyte's strategic collaboration with Genesis Therapeutics to develop novel small molecule medicines using AI could enhance its drug discovery capabilities and pipeline diversity. (stocktitan.net)
Insider selling activity, including the sale of 6,043 shares by EVP Vijay K. Iyengar, may raise concerns about internal confidence in the company's future performance. (etfdailynews.com)
Analysts have issued mixed ratings, with Cantor Fitzgerald maintaining a 'neutral' stance, suggesting potential uncertainty about Incyte's growth prospects. (americanbankingnews.com)
Increased R&D and SG&A expenses have contributed to an earnings miss in Q4 2024, raising concerns about the company's cost management and profitability. (monexa.ai)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
Incyte Financial Performance
Revenues and expenses
Incyte Earnings Performance
Company profitability
Incyte News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Incyte stock?
Incyte (INCY) has a market cap of $13B as of July 01, 2025.
What is the P/E ratio for Incyte stock?
The price to earnings (P/E) ratio for Incyte (INCY) stock is 704.66 as of July 01, 2025.
Does Incyte stock pay dividends?
No, Incyte (INCY) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next Incyte dividend payment date?
Incyte (INCY) stock does not pay dividends to its shareholders.
What is the beta indicator for Incyte?
Incyte (INCY) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.